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Abstract
In light of an aging population with increased cardiovascular comorbidity, the use of oral anticoagulation (OAC) is
steadily expanding. A variety of pharmacological alternatives to vitamin K antagonists (VKA) have emerged over recent
years (direct oral anticoagulants, DOAC, i.e., dabigatran, rivaroxaban, apixaban, and edoxaban) which show a reduced
risk for the occurrence of intracerebral hemorrhage (ICH). Yet, in the event of ICH under OAC (OAC-ICH), hematoma
characteristics are similarly severe and clinical outcomes likewise substantially limited in both patients with VKA- and
DOAC-ICH, which is why optimal acute hemostatic treatment in all OAC-ICH needs to be guaranteed. Currently,
International Guidelines for the hemostatic management of patients with OAC-ICH are updated as several relevant
large-sized observational studies and recent trials have established treatment approaches for both VKA- and DOAC-ICH.
While the management of VKA-ICH is mainly based on the immediate reversal of elevated levels of international
normalized ratio using prothrombin complex concentrates, hemostatic management of DOAC-associated ICH is
challenging requiring specific antidotes, notably idarucizumab and andexanet alfa. This review will provide an overview
of the latest studies and trials on hemostatic reversal agents and timing and summarizes the effects on hemorrhage
progression and clinical outcomes in patients with OAC-ICH.
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Introduction
Of all stroke sub-types, intracerebral hemorrhage (ICH)
constitutes roughly 15% and is associated with the worst
prognosis [1–3]. Mortality amounts up to 50% after 1
year, and over two thirds of patients survive with signifi-
cant functional dependency [3, 4]. Over the last years,
randomized controlled trials investigating treatment op-
tions to influence functional outcome in general ICH
populations have failed to provide effective treatment
strategies [5–9]. Worldwide, the incidence of intracere-
bral hemorrhage (ICH) is increasing and primarily
driven by low- and middle-income countries [1]. Along-
side the demographic change in Western Hemisphere
countries, and increasing comorbidity requiring oral
anticoagulation (OAC), OAC-associated ICH represents
a growing dilemma [10].
Compared to general ICH cohorts, patients with
OAC-ICH are older, exhibit larger ICH-volumes, have
more frequent intraventricular hemorrhage (IVH), and
importantly have a greater frequency of hematoma ex-
pansion (HE), all of which are significant outcome pre-
dictors determining an even poorer prognosis [11–13].
In vitamin K antagonist (VKA)-associated ICH, the rate
of HE is described to occur in more than one out of
three patients although international normalized ratio
(INR) levels were not elevated beyond the therapeutic
range. Further, HE may occur protractedly even exceed-
ing 24 h, if anticoagulation status is not reversed [11–
13]. Comparing ICH occurring under use of direct oral
anticoagulants (DOAC) versus VKA provides at least
similar characteristics regarding validated ICH-specific
outcome predictors (neurological status, ICH-volume,
IVH, HE rates) and clinical outcomes [14–17]. Hence,
aggressive and specific medical management to reverse
altered coagulation irrespective of anticoagulant used is
essential to reduce HE rates and thereby to potentially
influence clinical outcomes [18].
Vitamin K antagonists
Over the decades, VKA have been the mainstay for anti-
coagulant treatment in patients with atrial fibrillation
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(A-fib) [19]. A dose-response relationship between
bleeding complications and supra-therapeutic inter-
national normalized ratio (INR) levels has been docu-
mented with a sharp incidence increase for INR levels
above 4 [20]. Nevertheless, ICH occurs commonly at
therapeutic INR levels exemplified by the largest avail-
able VKA-associated ICH cohort (n = 1176) reporting a
median INR level of 2.8 with an interquartile range be-
tween 2.3 and 3.5 [11]. While DOACs are currently re-
placing VKA as the primary drug in A-fib-patients, VKA
remains the primary anticoagulant for several patient
populations with high thromboembolic risk [21, 22].
Current American and International Guidelines for the
management of ICH patients do not provide specific
recommendations on how to treat VKA-associated ICH
in terms of a specific reversal strategy [3, 23]. Particu-
larly, INR values representing full reversal, timing of re-
versal, and reversal agents to be used are not addressed.
However, guidelines are currently being revised as sev-
eral high-quality publications have substantially added
knowledge to the field.
In 2015, a large observational multicenter study (n =
1176 patients with VKA-ICH) conducted across 19 ter-
tiary care centers in Germany addressed the questions
which INR levels should be achieved to most effectively
minimize HE [11]. Results showed (for 853 patients with
detailed follow-up imaging) that an INR of less than 1.3
was necessary to reduce the risk of HE (INR < 1.3, HE
rate = 27%, versus INR > 1.3, HE rate = 45%). This associ-
ation was stronger than the earlier achieved and signifi-
cantly present until 4 h after hospital admission
(achieved INR < 1.3 within 4 h, HE rate = 20% versus not
achieved HE rate = 42%). Notably, these data resulted
from a patient population that arrived roughly at a me-
dian of 2 h after symptom onset which is an important
factor to be considered as the risk for HE is greatest dur-
ing the hyper-acute time window (< 3 h), recently veri-
fied by a large (n = 5435) individual patient data meta-
analysis [24]. Therefore, it appears that earlier treatment
may translate into a greater effect size for HE preven-
tion. These large-sized investigations strongly support
that immediate as well as complete reversal is essential
to minimize HE in VKA-ICH, which has also been dem-
onstrated in patients requiring more intense anticoagula-
tion, i.e., mechanical heart valves [22]. In addition to
specific reversal treatment, the German multicenter
study suggested that lowering of systolic blood pressure
below 160mmHg provided further reductions of HE risk
and beyond sole imaging findings significantly reduced
in-hospital mortality (odds ratio (OR), 0.6, 95%CI 0.4–
0.9) [11]. In this regard, for general ICH populations, a
meta-analysis of five randomized controlled trials (n =
4360) investigating associations of an intensive blood
pressure lowering regime (targeting a systolic blood
pressure level < 140 mmHg) versus standard blood pres-
sure lowering (systolic blood pressure level < 180
mmHg) showed promising results for reduced HE rates
(OR 0.2; 95% CI 0.7 to 1.0, p = 0.06) and for death or de-
pendency rates at 3months (OR 0.9; 95%CI 0.8 to 1.0, p =
0.11). The current AHA guideline for the management of
ICH patients recommends to target systolic RR levels of
140mmHg during the acute phase of ICH [3, 25].
Agents to be used for reversal treatment have been in-
vestigated more thoroughly in general populations with
VKA-associated major hemorrhages or acute surgical in-
dications. One randomized phase IIIb, multicenter,
open-label, non-inferiority trial, in 202 patients with
VKA-associated hemorrhage (only 24 ICH-patients),
showed that abnormal coagulation was more rapidly re-
versed by vitamin K and 4-factor PCC (containing co-
agulation factors II, VII, IX, X) applied using staggered
dosing (INR 2–4: 25 IU/kg BW, INR 4–6: 35 IU/kg BW,
INR > 6: 50 IU/kg BW) compared to fresh frozen plasma
(FFP dosing, INR 2–4: 10 ml/kg, INR 4–6: 12 ml/kg, INR
> 6: 15 ml/kg), i.e., INR ≤ 1.3, achieved by PCC + vitamin
K in 62.2% versus FFP + vitamin K in 9.6% [26]. In an-
other phase 3 study (n = 181), patients with an INR ≥ 2.0
and acute indication for surgery using the same dosing
approach were randomized to receive either 4-factor
PCC at or FFP each combined with vitamin K. In the
PCC group, surgery could be started earlier after infu-
sion in the PPC group (median 3.6 h with interquartile
range (IQR) 1.9–10.8) compared to the FFP group (me-
dian 8.5 IQR, 2.8–18.7; p = 0.01) and the primary out-
come of effective hemostasis was achieved more
frequently with PCC (PCC 90% versus FF 75%; p = 0.01)
[27]. Both trials did show no signals regarding an un-
favorable safety profile of PCC. In patients with ICH, the
randomized controlled INCH trial included patients with
VKA-associated ICH and INR levels greater or equal to
2 on hospital admission to compare 4-factor PCC (30
IU/kg BW) versus FFP (20 ml/kg BW) both combined
with intravenous vitamin K (10 mg). The primary end-
point was the proportion of patients achieving an INR ≤
1.2 within 3 h, and the trial was prematurely stopped
after enrolment of 54 patients as HE rates significantly
differed between treatments [28]. A significantly larger
proportion of PCC-treated patients (67%) compared
with FFP (9%) reached the target INR of ≤ 1.2 after 3 h
(adj. odds ratio 30.6, 95% CI 4.7–197.9; p = 0.0003). After
24 h, patients in the FFP treatment group had greater in-
crease in ICH volume (absolute ICH volume difference
16.4 mL, 95% CI 2.9–29.9, p = 0.02) and had a fivefold
increased risk for HE, defined as a ICH volume increase
of greater 33% from initial to follow-up imaging (odds
ratio 4.5, 95% CI 1.3–20.4, p = 0.02). Although there was
a strong trend towards reduced 90-day mortality (PCC,
19% versus FFP, 35%), it did not reach statistical
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significance likely related to the small sample size [28].
Importantly, reversal in VKA-associated ICH should be
accompanied by simultaneous administration of slow
(15–30min) intravenous infusion of 10 mg vitamin K
(25 ml normal saline) to restore intrinsic hepatic carb-
oxylation of clotting factors and to achieve prolonged
hemostasis [29, 30]. Taken together, there is convincing
evidence to recommend immediate reversal in VKA-
associated ICH to INR levels < 1.3 as fast as possible and
to favor 4-factor PCC over plasma to influence HE rates
and clinical outcomes [31].
Management of VKA-associated ICH:
– Immediate INR reversal using 4-factor PCC (25–50
IU/kg BW) and vitamin K (10 mg)
– Targeting complete reversal INR < 1.3 as soon as
possible, at least within 4 h
– Timely and serial INR measurements within the
acute phase
– Intensive systolic blood pressure reduction, targeting
140 mmHg
– Avoid hypotension, i.e., systolic blood pressure level
below 100–120 mmHg
Direct oral anticoagulants
Currently marketed non-VKA anticoagulants comprise
three factor-Xa inhibitors (apixaban, edoxaban, rivaroxa-
ban, inhibition of the conversion of prothrombin to
thrombin) and the direct thrombin-inhibitor dabigatran
(competitive inhibitor of thrombin, thereby inhibiting fi-
brin production), all of which are now recommended for
primary or secondary stroke prevention in patients with
atrial fibrillation over VKA [19]. Compared to VKA
these DOACs share similar pharmacokinetic properties
such that elimination half-life is short ranging from 6 to
17 h across agents in patients with normal renal function
[32]. Therefore, effective OAC may theoretically not be
present on admission, but importantly cannot be timely
and validly excluded by routine diagnostics [33, 34].
Using conventional coagulation testing does not provide
sufficient sensitivity or specificity, and currently, no data
is available suggesting a definite threshold for all DOACs
below which one can exclude DOAC effect [33]. For a
rough qualitative estimate of altered hemostasis in
DOAC-treated patients in general, thrombin time (TT),
prothrombin time (PT), and/or activated partial
thromboplastin time may be used. More specifically, if
available, quantitative assessment (time-consuming,
roughly 30 min) of dabigatran levels may be achieved
with the dilute thrombin time (dTT), ecarin clotting
time (ECT), and for apixaban, edoxaban, and rivaroxa-
ban with agent-specific anti-factor Xa levels, further
point-of-care testing devices are currently under devel-
opment or evaluation [33, 34]. Hence, patients with
known DOAC intake and ICH should all receive imme-
diate reversal treatment. Timing of last DOAC intake is
important as early treatment (2–4 h after ingestion) with
active charcoal (50 g), if safely tolerable by the patient,
may have the potential to reduce drug absorption [35].
Other more general options may theoretically comprise
hemodialysis in dabigatran-related bleedings, but this
seems not to be a sensible option in ICH where immedi-
ate reversal must be achieved. Currently, DOAC reversal
comprises specific and unspecific approaches which will
be highlighted in the following.
Specific reversal antidotes
In DOAC-associated major hemorrhages or patients re-
quiring emergency surgery, several prospective, multi-
center, open-label studies investigating the effectiveness
of reversal agents are available [36, 37]. Yet, specific ana-
lyses of patients with ICH from these studies are not
published yet. Reversal agents differ regarding phar-
maco- mechanistic and kinetic properties as well as ef-
fectiveness across the various DOAC agents. Therefore,
at the current stage, there is no evidence regarding the
effectiveness of reversal agents to influence HE rates or
clinical endpoints in DOAC-associated ICH.
Ciraparantag for DOAC-associated ICH
Ciraparantag (syn.: PER977, aripazine), a small molecule
(520 Da), was designed to reverse anticoagulatory effect
of heparinoids, direct thrombin, and factor-Xa inhibitors
and is currently investigated in phase II trials
(NCT03172910, NCT03288454). The broad application
seems to be an advantage, especially as rapid onset of ac-
tivity, single-dose application, and long duration of effect
have been suggested [38]. A recent phase I/II investiga-
tion in 82 healthy male subjects has reported that antic-
oagulation of edoxaban (60 mg) was reversed within 10–
30min as well as over 24 h by a single-dose ciraparantag
(100–300 mg), without increasing procoagulant mea-
sures (d-dimer, prothrombin fragments 1.2, and tissue
factor pathway inhibitor levels) [39]. Ciraparantag re-
ceived fast-track designation in 2015; however, currently,
it remains uncertain whether or when this agent will be
further evaluated in controlled trials targeting FDA ap-
proval and market release.
Idarucizumab for dabigatran-associated ICH
Specific reversal of dabigatran can be achieved with idar-
ucizumab, which is a non-competitive inhibitor and rep-
resents a humanized monoclonal antibody fragment
binding to dabigatran with high affinity (350 times
greater than thrombin). The formation of this complex
between idarucizumab and dabigatran is almost irrevers-
ible; hence, anticoagulation persistently reversed, and
this complex renally excreted [36, 40]. Idarucizumab
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(Praxbind®) is administered as two intravenous boluses
(2 × 2.5 g) within 15 min and gained approval by the
European Medicines Agency (EMA) and Federal Drug
Administration (FDA) in 2015 for reversal of dabigatran-
associated life-threating bleeding complications or for
patients requiring emergency surgery.
The full-cohort analyses of the open-label REVERSE-
AD study was published in 2017, comprised overall 503
patients grouped into patients with uncontrolled
hemorrhage (group A, n = 301) or in need for urgent in-
vasive procedures (group B, n = 202) [36]. The primary
endpoint consisted of the maximum percentage reversal
of the anticoagulant effect, measured by the dTT or
ecarin-clotting time within the first 4 h after infusion of
idarucizumab. Results provided for the entire cohort that
on admission 92% of patients had prolonged bleeding
measures and 4 h after reversal treatment the median
maximum percentage reversal was 100% [36]. For group
A, including 98 patients with intracranial hemorrhage of
which 53 patients experienced ICH, the median level of
unbound dabigatran was initially 110 ng/ml and after re-
versal was 20 ng/ml and remained below this level for
24 h suggesting impairment of anticoagulation to be very
unlikely. In patients with intracranial hemorrhage, pro-
tocolized follow-up imaging was not mandated; there-
fore, effects on HE rates cannot be reported. In patients
with gastrointestinal hemorrhage (n = 137), further clin-
ical assessment showed that median time to bleeding
cessation was 2.5 h. For the entire cohort, the reported
thromboembolic event rate was 5% (24/503) within 30
days and in patients with ICH 6% (3/53) experienced a
thromboembolic event, all occurring more than 10 days
after idarucizumab administration [36].
Mechanistically, idarucizumab is not expected to gen-
erate an intrinsic prothrombotic risk, and the reported
events are likely to be associated with the underlying
disease. Data specifically in ICH patients is very limited,
and smaller case series based on a prospective German
nation-wide observational study reported HE rate of
25% (2/8) after reversal with idarucizumab theoretically
reflecting a HE rate comparable to VKA-associated ICH
patients being reversed to INR levels below 1.3 [41].
Even though randomized data and detailed analysis of
ICH patients is lacking, findings of the REVERSE-AD
study for dabigatran-associated ICH suggest that the
specific antidote idarucizumab provides a rapid, suffi-
cient, and prolonged reversal of anticoagulation effect
and should be immediately administered after diagnosis
of ICH as two intravenous boluses (2 × 2.5 g) within 15
min [36].
Andexanet alfa for factor-Xa-inhibitor-associated ICH
Specific reversal of factor-Xa-inhibitors (rivaroxaban,
apixaban) can be accomplished with andexanet alfa
(Andexxa®) which has been approved in May 2018 by
the FDA. Andexanet alfa has been designed to reverse
the anticoagulant activity of both direct and indirect
factor-Xa-inhibitors [42]. Andexanet alfa acts as a hu-
man decoy receptor binding to the active site of factor-
Xa inhibitors with high affinity and possesses no cata-
lytic activity [42]. Therefore, factor-Xa activity is sup-
posedly restored and effect of anticoagulation
attenuated. Several studies in healthy subjects have been
conducted to evaluate the potential of reversing anticoa-
gulation. More specifically, a two-part randomized con-
trolled phase 3 trial (ANNEXA-A and ANNEXA-R)
evaluated effectiveness of andexanet alfa in healthy older
volunteers taking either apixaban (ANNEXA-A, n = 24)
or rivaroxaban (ANNEXA-R, n = 27) comparing different
dosing (400–960mg) and application regimes (single
bolus and bolus followed by 2-h infusion) [43]. Study re-
sults showed that in over 90% anti-Xa activity was re-
duced during time of treatment with andexanet alfa
followed by a rebound after end of infusion [43].
Currently, the phase 4 study (NCT02329327) is on-
going, and most recently, the full study report has been
published [37]. For this multicenter, prospective, open-
label, single-group study patients with factor-Xa inhibi-
tor (apixaban, edoxaban, rivaroxaban, and enoxaparin)
associated hemorrhages within 18 h after the last intake
has been published. The coprimary outcomes were the
percent change in anti-factor-Xa activity after andexanet
treatment and the percentage of patients with excellent
or good hemostatic efficacy at 12 h after the end of the
infusion, as pre-specified [37]. The treatment protocol
comprised a bolus infusion over 15 to 30min followed
by a 2-h infusion, with different dosing dichotomized ac-
cording to last known intake, i.e., intake within the last
7 h or unknown status received a higher dose of 800 mg
over 30 min followed by 960 mg, and last intake > 7 h re-
ceived 400 mg followed by 480 mg. Included patients
(n = 352) exhibited dominantly intracranial hemorrhages
in 64% (n = 227/352), including 241 ICH patients, and
20% with gastrointestinal hemorrhages [37]. By study de-
sign efficacy, analysis was conducted for 254 patients
and results showed a decrease in anti-factor-Xa activity
in over 90% in apixaban and rivaroxaban and in 75% of
enoxaparin-treated patients measured 4, 8, and 12 h after
infusion. Predefined excellent or good hemostasis
assessed 12 h after the end of infusion was achieved in
82% (95% CI 77–87%) of patients.
Specifically, focusing on patients with ICH, study re-
sults are not published but have been reported at the
International Stroke Conference 2019. In 71 ICH pa-
tients eligible for efficacy analyses, HE was reported in
15 patients assessed at 1 h and in 1 patient assessed at
12 h. Therefore, the HE rate can be considered to be at
22% (n = 16/71) in ICH patients after andexanet
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infusion, theoretically again comparable to dabigatran-
associated and VKA-associated ICH patients receiving
reversal treatment. Interestingly, for the entire cohort,
no correlation between hemostatic efficacy and de-
creased anti-factor-Xa activity was noted, but in ICH pa-
tients, a moderate correlation could be shown as area
under the curve of 0.64, 95% CI (53–74). A debated mat-
ter of concern for this study was the reported throm-
botic event rate of 10% (n = 34/352) including 4% (n =
15) with ischemic stroke and 4% (n = 13%) with deep
vein thrombosis in light of elevated laboratory surrogates
(d-dimer, prothrombin fragments 1 and 2). ANNEXA-4
is still ongoing to further evaluate also patients with
edoxaban associated hemorrhages and for more detailed
analyses of ICH patients. However, comparing the esti-
mated treatment cost (based on US data) of reversal
agents suggests a large discrepancy between idarucizu-
mab (5495 USD) or 4-factor PCC (4000 IU, 5080 USD)
and andexanet alfa ranging between 24,000 and 48,000
USD [32, 44]. So far, andexanet alfa is only approved in
the USA. The European Medicines Agency (EMA) has
agreed to consider andexanet alfa (Ondexxya®) for fast
track approval provided results of the ongoing trial. Out-
side the USA, andexanet alfa can (theoretically already
now) be purchased through international pharmacies at
extremely expensive costs.
In summary, for factor-Xa inhibitor-related ICH,
through providing fast and sufficient effect on
hemostasis, andexanet alfa harbors several limitations
which make administration more complex as compared
to idarucizumab. The hemostatic rebound, the need for
continuous infusion, the reported prothrombotic com-
plications, and the financial aspects bare the risk that
andexanet alfa will ultimately not be used as frequently
as necessary. In addition, similar to idarucizumab, data
on HE rates and clinical outcomes are necessary in order
to verify clinical relevance of andexanet alfa in ICH pa-
tients [36, 37].
Unspecific reversal approaches
PCC for factor-Xa inhibitor-associated ICH
Three categories of human plasma compounds—pro-
thrombin complex concentrates (PCC)—are currently
available to restore altered coagulation, i.e., 3-factor PCC
(II, IX, X), 4-factor PCC (II, VII, IX, X), and activated
PCC (activated VII, II, IX, X, FEIBA) [34]. Experimental
data and mostly phase I randomized data have suggested
that PCC may have potential to reverse anticoagulation
induced by factor-Xa inhibitors [45–48]. For direct com-
parisons of these factor concentrates, most data is
present for anticoagulation treatment with rivaroxaban
and edoxaban suggesting effects of 4-factor PCC over 3-
factor PCC and FEIBA being comparable if not superior
to 4-factor PCC to reverse coagulation. A small cross-
over study in 10 healthy volunteers, treated with dabiga-
tran and rivaroxaban, suggested that thrombin gener-
ation was improved best by activated 4-factor PCC
measured by ex vivo hemostatic testing of PCC deriva-
tives in rivaroxaban-treated but not in dabigatran-
treated patients [46]. Direct human in vivo comparisons
between FEIBA and 4-factor PCC are not available. Clin-
ically more convincing are data investigated in 35
healthy individuals receiving PCC, comparing 3-factor
with 4-factor PCC, which showed for both agents pos-
sible reversal properties after rivaroxaban treatment [47].
The largest randomized study was conducted in 110
healthy edoxaban-treated (single dose 60mg) individuals
and compared dosing regimens using 4-factor PCC (50
IU/kg BW, 25 IU/kg BW, 10 IU/kg BW) and determined
effect based on bleeding duration and volume after der-
mal punch biopsy. Results provided that PCC adminis-
tered only at 50 IU per kg body weight influenced both
bleeding endpoints supporting a potential role for in un-
specific reversal [48]. No adverse events occurred that
were adjudicated to be related to the study medication.
In patients with major hemorrhagic complications
and/or ICH under use of rivaroxaban or apixaban, a pro-
spective cohort study (n = 84) including 59 patients with
intracranial hemorrhage investigated associations of 4-
factor PCC with hemostasis rate, as defined per study
protocol [49]. For the entire cohort, the median PCC
dose was 2000 IU (IQR 1500–2000) or 27 IU/kg BW and
“effective” hemostasis was scored in 69% (n = 58/84) of
patients. For patients with intracranial hemorrhage, inef-
fective hemostasis was reported in 27% (16/59), confer-
ring to similar HE rates as available for reversal with
andexanet or idarucizumab [49]. The thromboembolic
rate however was rather low with 4% (3/84). One of the
first larger observational studies (n = 61) in ICH patients
did not show signals that PCC was influencing HE rates
(43% n = 12/28 received PCC versus 29% n = 5/17 with-
out PCC, p = 0 .5) [17]. The largest available cohort
study (n = 190; rivaroxaban, n = 142; apixaban, n = 26;
dabigatran, n = 22) was based on the follow-up study
(2010–2015) from the German-wide multicenter study
(RETRACE-program) and, according to study protocol,
included only patients with ICH under known DOAC
use [14]. For the differing DOAC agents observed HE
rates in patients with detailed follow-up imaging were
33% for rivaroxaban, 48% for apixaban, and 20% for
dabigatran, which were not statistically different, but lar-
ger sample sizes would be required to determine poten-
tial DOAC class associations. Specific analyses of HE
rates according to reversal strategies provided that
across all agents the median PCC dose given was 2000
IU for rivaroxaban (IQR 1500–2600) and dabigatran
(IQR 1650–3000) and 2400 IU for apixaban (IQR 1500–
3000). But it has to be recognized that overall less than
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half of all patients received appropriate dosing (dose ≥
25 IU/kg BW; 44%, n = 65/146) which was recommended
during that treatment period.
Current consensus recommendations support higher
dosing with 50 IU/kg BW or greater, and within that
study, only 5% of patients were treated accordingly;
therefore, sensible analyses of this higher-dosed regime
was not executable. Upon adjusted analyses, this multi-
center study provided no effect of PCC reversal on re-
duction of HE rates in factor-Xa inhibitor-associated
ICH (risk ratio 1.06, 95%CI 0.56–1.98) or on clinical
endpoints. However, it is always important to identify
patients with high re-bleeding risk in whom aggressive
medical treatment possesses greater effect size. For rivar-
oxaban specific anti-Xa-activity levels of greater of 118
ng/ml were identified to be significantly associated with
increased HE risk (level > 118 ng/ml, HE rate 56% versus
level ≤ 118 ng/ml, HE rate 17%; p = 0.01). Upon further
categorizing sub-group analyses, no other association,
but systolic blood pressure reduction (< 160 mmHg, risk
ratio 0.6, 95% CI (0.36–0.98), p = 0.04), could be identi-
fied as protective on HE. Therefore, available data sug-
gests that 4-factor PCC at a dose of 50 IU/kg BW may
be considered as “second-line” treatment in factor-Xa-
inhibitor-associated ICH, if andexanet is unavailable.
Other hemostatic agents
Recently, a large randomized trial (n = 2325) investigated
the effect of the anti-fibrinolytic agent tranexamic acid
(1 g Bolus, followed by 1 g infusion over 8 h) on func-
tional outcome after 90 days in patients with primary
ICH, but per study protocol excluded patients with OAC
[6]. Results provided no significant effect on functional
outcome, yet sub-analyses suggested a significant rela-
tion with reduced HE (ICH volume > 33%; binary odds
ratio 0.8, 95%CI (0.66–0.98), p = 0.03). Nevertheless,
clinical data on associations of tranexamic acid in OAC-
associated hemorrhage are sparse. The large inter-
national trial (n = 20.211), Effects of tranexamic acid on
death, vascular occlusive events, and blood transfusion in
trauma patients with significant haemorrhage (CRASH-
2), showed a significant risk reduction for bleeding-
associated death (relative risk 0.85, 95% CI (0.76–0.96);
p = 0·008) and did not exclude anticoagulated patients as
the study protocol incorporated an uncertainty principle,
but OAC use was unlikely in this fairly young (mean age
35 years) study population [50]. Post hoc analyses in
traumatic brain injury also provided a decrease of intra-
cranial hemorrhage progression but data on association
with OAC are not present [51], but may possibly be gen-
erated from the follow-up trial CRASH-3 in traumatic
brain injury (NCT01402882). Nevertheless, a smaller
multicenter RCT is currently enrolling patients to evalu-
ate tranexamic acid application in DOAC-associated
ICH (TICH-NOAC, NCT02866838), yet available ex-
perimental data does not support this hypothesis [52].
Following the negative results and safety concerns with
an increased rate of thromboembolic complications in
the FAST Trial, a phase 3 study on the efficacy of re-
combinant activated factor VII (rFVIIa) in ICH patients,
administration of rFVIIa is currently not recommended
[53], yet ex vivo and in vitro studies suggest reversal ef-
fects of rivaroxaban and apixaban by recombinant FVIIa
[54]. Another consideration refers to patients under dual
therapy—OAC and concomitant antiplatelet medica-
tion—which is present in roughly 10% of patients (n =
290/2504) possibly necessitating adjunctive therapies
such as platelet transfusions or desmopressin (DDAVP)
treatment [55]. For treatment with platelet transfusions,
randomized phase 3 trial data (n = 190) in antiplatelet-
associated ICH suggests a negative association with
functional outcome at 3 months (adjusted common odds
ratio 2.05, 95% CI (1.18–3.56); p = 0.01) and increased
severe adverse events (adjusted common odds ratio 1.79,
95% CI (0.98–3.27)) [5]. Meta-analyses for DDAVP treat-
ment (0.4 mcg per kg BW) in patients with platelet dys-
function or with antiplatelet medication support DDAVP
use in patients undergoing surgery to reduce bleeding
and transfusion requirements [56]. Specifically, in ICH
patients, data is very limited but suggests associations
with improved platelet activity [30].
Management of DOAC-associated ICH:
– Consider per oral charcoal (50 g), if last intake < 4 h
and safe for the patient
– Intensive systolic blood pressure reduction, targeting
140 mmHg
– Avoid hypotension, i.e., systolic blood pressure level
below 100–120 mmHg
– Dabigatran-associated ICH, immediate reversal
using Idarucizumab (2 × 2.5 g)
– Factor-Xa inhibitor-associated ICH, immediate spe-
cific reversal using andexanet alfa (unknown time
window or last intake ≤ 7 h, 800 mg over 30 min
followed by 960 mg over 2 h, last intake > 7 h, 400
mg over 15 min followed by 480 mg over 2 h)
– Factor-Xa-inhibitor-associated ICH, immediate
unspecific reversal using high-dose 4-factor PCC or
activated PCC (both 50 IU/kg BW)
– Consider serial specific coagulation measurement to
monitor reversal (dabigatran, dTT, ECT; factor-Xa
inhibitors, agent-specific anti-Xa activity).
Conclusions and future directions
Significant progress has been achieved recently in large
studies for the acute management of patients with OAC-
ICH. All these therapeutic interventions mainly focus on
reducing the occurrence and extent of hematoma
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enlargement (please see Fig. 1). On the one hand, blood
pressure management targeting systolic levels of 140
mmHg has been verified to limit hematoma expansion
and thus should be maintained attentively. On the other
hand, optimal hemostatic management significantly re-
stricts hemorrhage progression in all types of OAC-ICH.
Specifically, in patients with VKA-ICH, complete rever-
sal of elevated INR levels using prothrombin complex
concentrates needs to be initiated immediately to
stabilize the intracerebral hematoma. In patients with
dabigatran-related ICH, prompt administration of the
antidote idarucizumab achieves rapid hemostasis. Al-
though clinical data of minimizing hematoma enlarge-
ment by idarucizumab are pending, the likelihood
thereof results in a clear recommendation for idarucizu-
mab in dabigatran-ICH. For patients with factor-Xa-
inhibitor-associated ICH, andexanet alfa has been dem-
onstrated to provide sufficient hemostasis and first un-
published data suggest effects on reducing hematoma
progression in these patients. However, andexanet alfa
currently is approved by the FDA only, whereas it is not
available elsewhere in the world, and moreover has not
been verified for treatment of all factor-Xa-inhibitors.
Hence, hemostatic reversal management for factor-Xa-
inhibitor-associated ICH remains challenging. Although
not sufficiently backed by hemostasiological data, and
no formally verified safety analysis, International Guide-
lines recommend prothrombin complex concentrates
administration in dosages of 50 IU/kg bodyweight. Ob-
servational analysis on prothrombin complex
concentrates administration in factor-Xa-inhibitor-asso-
ciated ICH showed conflicting data on whether or not
there are associations with reduced hemorrhage progres-
sion. Two major aspects need to be resolved in timely
fashion: firstly, it requires a verification that antidotes, or
other prothrombotic drugs respectively, significantly
limit hematoma expansion and impact clinical out-
comes, and secondly, the all over availability of those
drugs needs to be ensured given an increasing world-
wide demand.
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